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Abstract 
Aim: 
            To describe the demographics, management and outcomes of children admitted with 
laboratory-confirmed cryptococcosis at three Johannesburg hospitals from 2002-2011. 
Method:  
Records of patients younger than 14 years of age who were diagnosed with 
cryptococcosis (as identified by review of the GERMS-SA surveillance) over the 10 year study 
period were reviewed using a structured data collection tool. The patients were managed in the 
Paediatric Departments at Chris Hani Baragwanath Academic Hospital (CHBAH), Charlotte 
Maxeke Johannesburg Academic Hospital (CMJAH) and Rahima Moosa Mother and Child 
Hospital (RMMCH).  
Results: 
Forty-eight children under 14 years of age were included in this study. The median age 
was 9.6 years (Interquartile Range (IQR), 7.0 to 11.8 years), most of them (31/48, 64.6%) were 
boys and 27 (56.3%) were from CHBAH. Thirty-eight (79.2%) were HIV positive with very low 
CD4 counts (n=26; median 13 cells/mm3; IQR, 5 to 144 cells/mm3). Of the eight HIV negative 
patients, one had leukaemia, two were neonates and five had no known underlying 
predisposing condition. 
Children with cryptococcosis presented for care mainly with headache (60.5%), vomiting 
(59.5%) and fever (43.2%). Twenty-four (50.0%) had cryptococcal meningitis, 14 (29.2%) had 
meningitis with concomitant cryptococcaemia, and 10 (20.8%) had cryptococcaemia without 
meningitis.  Children with cryptococcal meningitis were 7.5-fold (95% CI, 1.31 to 51.93) more 
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likely to have been treated with amphotericin B compared to those who had fungaemia without 
meningitis, P=0.001. 
Nineteen (39.6%) patients were started on anti-tuberculosis treatment during the course 
of their hospitalisation with cryptococcosis. Five (41.7%) of the 12 children on fluconazole and 
concomitant TB treatment were on boosted fluconazole dosage regimens (i.e., >10 mg/kg/day). 
Twelve (31.6%) of the 38 HIV positive children with cryptococcosis were not sent home on 
fluconazole prophylaxis. 
Ten (20.8%) children died during the course of their hospital admission.  
Conclusion: 
          Paediatric cryptococcosis is a rare condition. HIV infection is an important predisposing 
condition to cryptococcal disease. There appeared to be widespread deviation from published 
guidelines in terms of treating patients with fluconazole at public health facilities in Gauteng 
Province. Clinicians caring for children with cryptococcal disease should seek advice from 
infectious disease clinicians in order to optimise patient care.  
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1.0: Introduction 
 
1.1 An overview of the pathogenic Cryptococcus species 
 
Cryptococcal disease is caused by the encapsulated yeast, Cryptococcus, of which the 
two most commonly pathogenic species are Cryptococcus neoformans and Cryptococcus gattii. 
These are closely-related pathogenic yeasts and C. neoformans usually causes disease among 
patients with HIV infection and other immune-deficiencies whereas C. gattii has been observed 
to cause disease among immunocompetent patients [1]. In Africa C. gattii has also been 
reported to cause disease in both immunocompromised and immunocompetent patients [2].   
Cryptococcal disease is acquired through the inhalation of infectious particles found in 
the environment, usually associated with desiccated pigeon droppings [3]. The infection may 
remain dormant in the lung until such time as a patient becomes immune compromised, after 
which it may spread haematogenously to any part of the body. The disease spectrum includes 
infection of the bone, bloodstream, central nervous system, kidneys, liver, lymph nodes, skin 
and spleen [4, 5].  
 
1.2 Cryptococcal Disease: Diagnosis, Clinical Manifestations and Treatment 
 
Cryptococcal meningitis is the most common presentation of human immunodeficiency 
virus (HIV)-related cryptococcal disease among adults, and has case fatality ratios as high as 
35%-65% in sub-Saharan Africa [6, 7]. The clinical presentation of cryptococcal meningitis 
among adults is typically that of a sub-acute meningitis with varying combinations of fever, 
13 
 
headache, nausea, vomiting and cognitive dysfunction [8] . Focal neurological signs and 
seizures may also be present [8]. The most significant markers for poor clinical outcomes are an 
altered mental status, a persistently raised intracranial pressure (>20 cm H2O) and a CD4 count 
less than 100 cells/mm3  [8]. 
A definitive diagnosis of cryptococcal meningitis is made through culture of 
Cryptococcus spp. in the cerebrospinal fluid (CSF). Alternative diagnostic approaches include 
India ink staining of CSF and the cryptococcal antigen test performed on blood and CSF 
specimens, which has a sensitivity of 95%, being more reliable than India ink staining [9, 10].  
A standard treatment regimen employs the use of the antifungal agents amphotericin B 
in combination with either flucytosine (where available) or fluconazole, starting with a two-week 
induction phase of amphotericin B (1mg/kg/dose, administered as an intravenous infusion daily) 
followed by eight weeks of oral fluconazole[11].  A secondary prophylaxis phase of treatment 
follows in which oral fluconazole is given for life or until the patient’s CD4 count is >200 
cells/mm3 for more than 12 months [9, 10]. Flucytosine, co-administrated with amphotericin B 
during the induction phase of treatment, is the treatment of choice according to international 
guidelines; however, flucytosine is not available in South Africa [10, 11]. 
In the developed world, with increased use of antiretroviral therapy (ART), the incidence 
of cryptococcal disease has decreased considerably amongst HIV-infected patients [7]. In 
resource-limited settings, treatment of HIV-positive patients with antiretrovirals often occurs 
when patients are already severely immunocompromised, and because cryptococcal disease 
occurs more commonly among patients with low CD4 counts (<100 cells/mm3), the burden of 
the disease has remained high despite increasing access to ART [7, 12]. Cryptococcal disease 
still accounts for as many as 10%-20% of all deaths in HIV-positive cohorts in sub-Saharan 
Africa, causing an estimated  500,000 deaths annually in this region [13]. 
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1.3 Paediatric Cryptococcal Disease 
 
Cryptococcosis occurs among children but is unaccountably less common than among 
adults [14]. Even in sub-Saharan Africa which has the highest prevalence of co-infection with 
HIV and Cryptococcus, cryptococcosis is rare in children [15]. A report from Gauteng Province 
in South Africa documented a total of 2,753 cases of cryptococcosis between 2002 and 2004, 
with only 24 (0.9%) of those being younger than 15 years of age [15, 16]. A similar prevalence 
(1%) for childhood co-infection with HIV and Cryptococcus was estimated from early studies in 
the United States [14]. In a South African study comparing paediatric and adult-onset 
cryptococcosis from 2005-2007, there was a bimodal distribution of cryptococcal disease among 
children, firstly among neonates and infants, and secondly among school-going and adolescent 
children [17]. There is still a scarcity of data on perinatally-acquired, neonatal, and paediatric 
cryptococcosis, including its clinical presentation and management, as compared to adult 
cryptococcal disease [18, 19]. 
 
1.4 The Current Status of Cryptococcal Disease Treatment Guidelines 
 
There are currently no specific treatment guidelines for children with cryptococcal 
disease, and treatment recommendations are based on data obtained through treating adults 
[10]. The World Health Organization (WHO) pocketbook of hospital care for children describes 
recommendations on the treatment of cryptococcal meningitis [20] and the WHO Rapid Advice 
document which was published in December 2011 also gives recommendations on the 
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diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, 
adolescents and children [11]. The WHO Rapid Advice document makes six key 
recommendations, based on data available for adults:  
1. The diagnosis of cryptococcosis should be made early in severely 
immunocompromised patients through the use of lumbar puncture (LP) and 
cryptococcal antigen testing of CSF; 
2. Primary prophylaxis (using oral fluconazole) is currently not recommended routinely in 
HIV-infected patients with CD4 counts <100 cell/mm3, unless a prolonged delay in ART 
initiation is likely. Screening for Cryptococcus in adults (but not adolescents and 
children) with CD4 counts <100 cells/mm3 before ART initiation and starting 
appropriate antifungal therapy is recommended, however; 
3. For patients with cryptococcal disease, a treatment induction phase with amphotericin 
B and flucytosine (or fluconazole where flucytosine is not available) is recommended. 
Induction regimens with fluconazole and flucytocine or high-dose fluconazole 
monotherapy are recommended where amphotericin B is not available. An eight week 
consolidation phase of treatment with oral fluconazole, and secondary fluconazole 
prophylaxis are recommended after the induction phase; 
4. Prevention, monitoring and management of amphotericin B toxicity is recommended  to 
minimize hypokalaemia and nephrotoxicity associated with the use of amphotericin B; 
5. ART should be started after four weeks of antifungal treatment in HIV-positive patients 
newly diagnosed with cryptococcosis. This recommendation safeguards against the 
adverse outcome of immune reconstitution inflammatory syndromes (IRIS) related to 
residual cryptococcal disease;  
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6. Secondary prophylaxis can be discontinued in HIV-positive adult patients with 
successfully treated cryptococcal disease after at least 12 months on the antifungal 
therapy, if they are adherent to ART and immune reconstituted [11].  
Paediatric recommendations are similar to those for adults although the evidence base is 
not as robust. The Southern African HIV Clinicians’ Society guidelines on the prevention, 
diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-
positive adult patients [10] have been widely used in the Southern African region as a guide for 
the treatment of cryptococcosis among children. 
 
1.5 Cryptococcal Surveillance 
 
The National Institute for Communicable Diseases (NICD) has conducted ongoing 
population based surveillance for cryptococcal disease in South Africa since 2002. A 
comparison of paediatric and adult onset cryptococcosis detected through population-based 
surveillance in South Africa from 2005-2007 showed 361 (2.2%) of the 16,192 episodes of 
cryptococcosis in South Africa occurred among children (<15 years) and the highest incidence 
was documented in infants <12 months of age [17]. Although most patients with cryptococcosis 
were HIV-positive, there was a higher proportion of HIV-negative children (9%) compared to 
HIV-negative adults (1%) with cryptococcosis [17]. A United States study which described the 
profile of cryptococcal disease between 2003-2008 also showed that the majority (63.5%) of 
children hospitalised with cryptococcal disease were HIV-negative, however they did have other 
immunocompromising medical conditions, including malignancies, immunological disorders and 
organ transplantation [21]. 
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1.6 Aim of the Study 
 
The aim of the study was to describe the demographics, management and outcomes of 
children younger than 14 years admitted with laboratory-confirmed cryptococcosis at three 
Johannesburg hospitals in the decade spanning 2002-2011. 
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2.0: Methods 
2.1 Design 
 
A cross sectional retrospective review of records of patients who were diagnosed with 
cryptococcosis from 01 January 2002 to 31 December 2011 was done and their presentation, 
management and outcomes were described. Details of the children with a positive 
microbiological diagnosis of cryptococcosis were obtained with permission from Dr Govender of 
the National Institute for Communicable Diseases’ GERMS-SA data-base. GERMS-SA is a 
nationwide active, prospective surveillance network which was established in 2005 in order to 
determine the epidemiologic trends of important infectious disease syndromes in South Africa 
[22].  
 
All cryptococcal fungal isolates arising from the study site microbiology laboratories are 
routinely sent to the NICD, Sandringham, Johannesburg and a case report form detailing patient 
characteristics is captured. Surveillance officers (trained enrolled and professional nurses) 
collect additional clinical and epidemiologic information on the laboratory confirmed cases. 
Occasionally, ‘audit cases’ are identified whose cryptococcal isolates were not reported to 
GERMS-SA, however such ‘audit cases’ represent a small fraction of all cases, and it is 
generally regarded that GERMS-SA data relating to cryptococcal disease in South Africa is 
reasonably complete. GERMS-SA is thus able to provide essential public health information to 
the Department of Health and other stakeholders. 
19 
 
The names and specimen numbers of the children under 14 years of age with 
laboratory-confirmed cryptococcal disease, as identified through the GERMS database, were 
used to access the patients’ clinical records and other blood results from the hospital records 
departments and the National Health Laboratory Service (NHLS) laboratory results system 
respectively. A manual review of the medical records was performed using a standardised data 
collection form (Appendix 1, page 43-48). Data collected included: demographics (age, gender), 
clinical presentation, co-morbidities (including HIV status and immunologic status (classified 
according to CD4 count) if available), treatment and outcomes.  
 
2.2 Study Sites  
 
The study was conducted at three academic Paediatric Departments, based in hospitals 
affiliated with the University of the Witwatersrand Faculty of Health Sciences in Johannesburg, 
South Africa. The hospitals include: Chris Hani Baragwanath Academic Hospital (CHBAH), 
Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) and Rahima Moosa Mother and 
Child Hospital (RMMCH). 
 
2.2.1 Chris Hani Baragwanath Academic Hospital (CHBAH)  
 
This is the largest hospital in the southern hemisphere with 2,888 approved beds, of 
which 2,639 are in use, and approximately 6,101 staff members (personal communication: B 
Phakathi, Data Manager, District Health System, CHBAH and Mrs L Roos, Principal personnel 
officer, Human Resources, CHBAH). It is located in Diepkloof, Soweto, south-west of 
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Johannesburg. The paediatric department has 371 paediatric beds, 58 of which are dedicated 
for haematology-oncology and cardiology. There are 134 neonatal beds including a 12-bed 
neonatal intensive care unit and 70 neonatal high-care beds. A further eight paediatric intensive 
care unit (ICU) beds are available in the general ICU. Approximately 65,000 outpatients are 
seen annually, including those seen at sub-specialty clinics (personal communication: B 
Phakathi, Data Manager, District Health System, CHBAH). The prevalence of HIV infection 
amongst the paediatric admissions at CHBAH was 19.3% in 2010-11[23]. Two specialised 
paediatric HIV clinics (Harriet Shezi Children’s Clinic and the Perinatal HIV Research Unit 
(PHRU)) are located at CHBAH.  
 
2.2.2 Charlotte Maxeke Johannesburg Academic Hospital (CMJAH) 
 
This centrally-located hospital in Parktown, Johannesburg, has 1,088 beds and about 
4,000 staff members. There are 58 general paediatric beds, 14 for haematology-oncology, 40 
neonatal beds and 14 high-care neonatal beds. The 11-bed paediatric ICU caters for neonatal 
and paediatric critical care patients. A third of the 60,000 paediatric outpatients seen annually 
attend sub-specialty clinics. The paediatric HIV clinic at CMJAH had supervised approximately 
2,000 children on ART as of February 2012 (personal communication: Dr S Varughese). 
 
2.2.3 Rahima Moosa Mother and Child Hospital (RMMCH)  
 
This maternity and paediatric hospital is located in Coronationville, in the western 
suburbs of Johannesburg. The paediatric department has 110 general beds and a six-bed ICU 
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for both neonatal and older children. 36,000 outpatients are seen annually, 15% of which attend 
sub-specialty clinics. Approximately 300 new HIV-positive patients presented to the RMMCH 
paediatric HIV clinic in 2011, a decrease from 440 patients in 2008. The HIV infection 
prevalence in the paediatric wards at RMMCH was 26% in 2010 (personal communication: Dr C 
Technau). 
 
2.3 Study Population  
 
The following inclusion criteria were used to derive the study population: 
1. Positive cryptococcal antigen test and/or positive Cryptococcus culture on blood or 
CSF, and/or positive India ink test on CSF. For each patient only the first episode of 
cryptococcal disease was included;  
2. Paediatric patients from birth to 14 years. The date of cryptococcal disease diagnosis 
from the NICD records , the date of admission and the birth dates from the medical 
records were used to determine the patients’ ages; 
3. Admitted to CHBAH, CMJAH or RMMCH in the period from 01 January 2002 through 
31 December 2011; 
4. Patient  clinical data recorded by GERMS-SA surveillance programme; 
5. Patient clinical notes available for review from the hospital records departments. 
Exclusion criteria which were chosen so as to limit the study population to paediatric, 
rather than adult cases of cryptococcosis, and to optimise the completeness of study data 
included: 
1. Children over 14 years of age; 
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2. Patient clinical notes missing. 
 
2.4 Data Collection  
 
The GERMS-SA database was used to retrieve details of the children that fitted the 
study inclusion criteria. Patient hospital files were sourced from the hospital records 
departments and the data collection form (Appendix 1, page 43-48) was used to obtain 
information for the study.  
Weight-for-age Z-scores (WAZ) were calculated in children under 10 years of age using 
WHO AntroPlus Software (WHO, Geneva), and underweight was defined as being a WAZ 
greater than -3.0, but less than WAZ -2.0. Children were classified as being “severely 
underweight” if their WAZ was less than -3.0[24].  
Immunologic status of the HIV positive children with available CD4 counts were 
classified according to the Centres for Disease Control and Prevention (CDC) immunologic 
classification system (Appendix 4, page 52)  [25]. 
 
2.5: Data Analysis 
 
Data were entered into an Excel spread sheet and thereafter imported into STATA 
version 12 (StataCorp, College Station, Texas) for analysis. Continuous data were described as 
means and standard deviations (SD) if normally distributed, or medians and interquartile ranges 
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(IQR) if skewed. The Student’s t test was used to compare means, and the Wilcoxon rank sum 
test was used to compare medians. 
Categorical data were described using frequencies and percentages, and proportions 
were compared using the Chi-square test or Fisher’s exact test, as appropriate. Odds ratios and 
95% confidence intervals (CI) were derived from the comparison of proportions between 
stratified groups. 
In all statistical analyses, two-sided p-values <0.05 were considered to be statistically 
significant. 
 
2.6: Ethics Clearance 
 
The study was approved by the University of the Witwatersrand Human Research Ethics 
Committee (reference number: M120357; Appendix 2, page 49). Administrative bodies of the 
three study site hospitals gave permission to perform a retrospective review of the hospital 
records (Appendices 3, page 50-52). The study protocol was presented to the Department of 
Paediatrics Postgraduate committee, which approved it as adequate for the requirements of a 
Masters of Medicine dissertation.  
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3.0: Results 
 
3.1: Demographics, HIV Status and Previous Medical History of the Cohort 
 
Fifty-eight paediatric cases with laboratory-confirmed cryptococcal disease treated at 
Paediatric Departments in the three study facilities were reported to the GERMS-SA 
surveillance system over the 10-year study period. Five of the 58 patients were older than 14 
years old and were thus excluded from the study. A further 5 patients were excluded from the 
study, because hospital records were lost and their clinical and outcomes data could not be 
described. There were therefore 48 patients included for analysis.  
The majority (31/48; 64.6%) of the children with laboratory-confirmed cryptococcal 
disease were male. There were six infants in total: three one-month-old infants, two that were 
two-months-old and one nine month old. The median age of all the children in the study was 
115.5 months (9.6 years; IQR, 7.0 to 11.8 years). The majority (27/48; 56.3%) of the study 
patients were from CHBAH, 16 (33.3%) were from CMJAH and five (10.4%) were from 
RMMCH.  
One patient was admitted to ICU and 42 (87.5%) were admitted to general paediatric 
wards. The five remaining patients were reported to have been managed in hospital outpatient 
departments, without confirmation that they had been admitted to hospital for treatment.  
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3.1.1: HIV Prevalence within the study population 
 
Forty-six (95.8%) patients had a documented HIV test and two had undefined HIV 
infection status. The majority (38/46, 82.6%) of the patients with defined HIV infection status 
were HIV-positive and the median age of the HIV positive children was 116.9 months (9.7 years; 
IQR, 7.7 to 12.0 years) . Twenty-seven (71.1%) of the HIV-positive patients had retrievable CD4 
results, and the median CD4 count was 13 cells/mm3 (IQR, 5 to 144 cells/mm3). Most of the 
HIV-positive children with available CD4 counts were classified as being severely 
immunocompromised according to the CDC paediatric immunologic criteria (Table 1). 
 
 <12 
months 
  
12-59 
months 
  
≥ 60 
months 
  
Total 
 
No immunosuppression 0 0 0 0 
Moderate immunosuppression 1 (50%) 0 4 (16.0%) 5 (18.5%) 
Severe immunosuppression 1 (50%) 0 21 (84.0%) 22 (81.5%) 
Number of children with available CD4 results 2 0 25 27 
Table 1: Immunologic classification of HIV-positive children diagnosed as having 
laboratory-confirmed cryptococcal disease 
 
Eighteen (47.4%) of the 38 HIV-positive children were on ART at the time of 
hospitalisation with their cryptococcal illness. The median CD4 count in HIV-positive children on 
ART (n=15; 48 cells/mm3; IQR, 10 to 289 cells/mm3) was significantly higher than the median 
CD4 count of those not yet on ART (n=12; 7 cells/mm3; IQR, 5 to 23 cells/mm3), P=0.034. 
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Of the eight HIV-negative patients, three were infants under one year of age and one 
had a malignancy. The median age of the HIV-negative children in the study was 82.7 months 
(6.9 years; IQR, 0.2 to 11.2 years).The underlying predisposing conditions for five of the HIV-
negative patients with cryptococcosis could not be determined by review of the clinical folders 
and three of these five were on anti-TB treatment during their admission.  
 
 
Age Gender 
Length 
of 
Hospital 
Stay 
(days) 
Site of 
Cryptococcal 
Infection 
Antifungal 
Treatment 
Administered 
Concurrent 
TB 
Predisposing 
Conditions Outcome 
1 6 years M 150 Blood Fluc No Malignancy (ALL) 
 
D/C 
2 9 years M 3 
Blood and 
CSF 
None Yes Undetermined 
 
Died 
3 12 years M 21 CSF 
Ampho B 
Fluc 
No Undetermined 
 
RHT 
4 11 years M 5 CSF None Yes Undetermined 
 
D/C 
5 6 years M 60 
Blood and 
CSF 
Ampho B 
Fluc 
Yes Undetermined D/C 
6 2 months F 12 CSF None No Undetermined 
 
D/C 
7 1 month M 1 CSF None No Neonate 
 
D/C 
8 1 month M 21 CSF 
Ampho B 
Fluc 
No Premature 
 
 
T/F 
Table 2: Clinical characteristics of eight HIV-negative children with laboratory-confirmed 
cryptococcosis 
F: female; M: male;  
CSF: cerebrospinal fluid; TB: tuberculosis 
Ampho B: Amphotericin B; Fluc: Fluconazole   
Rx: Treatment; ALL: Acute lymphoblastic leukaemia 
D/C: Discharged; T/F: Transferred to another facility 
RHT: Refusal of hospital treatment 
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Most of the HIV-negative children (7/8, 87.5%) had cryptococcal meningitis and one had 
cryptococcal fungaemia without meningitis. Half of these patients were treated for 
cryptococcosis and one out of the eight (12.5%) died. The clinical characteristics of the HIV-
negative children with laboratory-confirmed cryptococcal disease are summarised in Table 2. 
 
3.1.2 Previous Hospitalisation History  
 
Twenty five (52.1%) of the 48 paediatric laboratory-confirmed cryptococcal disease 
patients had never been hospitalised before. Their median age was 108.6 months (9.1 years; 
IQR, 6.5 to 11.0 years), and 17 (68.0%) were HIV-positive. The median CD4 count in the HIV-
positive children who had never been hospitalised before was 10 cells/mm3 (IQR, 6 to 34 
cells/mm3). ART status was known in 16 of the HIV-positive children who had never previously 
been hospitalised, and of those seven (41.2%) were on ART and nine (52.9%) were not on 
ART.  
Nineteen (39.6%) of the 48 patients included in the study had a history of one previous 
hospitalisation, of which 18 (94.7%) were HIV-positive. Four (8.3%) of the 48 study patients had 
more than two previous admissions, and three (75%) of them were HIV-positive. The HIV-
negative child who had had more than two previous hospitalisations was on TB treatment but no 
condition predisposing to cryptococcal disease could be determined in this child.  
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3.2: Clinical Presentation 
 
3.2.1 Anthropometric Parameters 
 
The study population was generally malnourished, with a median WAZ of -2.98 (IQR, -
3.53 to -1.74). The median WAZ in HIV-positive children was -2.99 (IQR, -3.53 to -1.80), 
compared to -1.80 (IQR, -3.68 to -1.54) in HIV-negative children, P=0.451. Overall, only three 
(10.3%) of the 29 children whose WAZ could be calculated had normal nutritional status. 
Numbers were too small to derive statistical significance in terms of degree of malnutrition, 
stratified by HIV infection status. 
 
3.2.2 Clinical Parameters at Admission 
 
The most common presenting symptoms were headache (23/38: 60.5%) and vomiting 
(22/37: 59.5%). Other symptoms mentioned in the history at presentation were fever (16/37: 
43.2%), seizures (9/37: 24.3%) and altered mental status (5/37: 13.5%) (Table 3). 
Axillary temperature at presentation was recorded in 42 patients, and 13 (31%) had 
fever (defined as a temperature >37.5 ˚C). The median temperature was 37.0 ˚C (IQR, 36.0 to 
38.0 ˚C). The median temperature at presentation in febrile patients was 38.0 ˚C (IQR, 38.0 to 
39.0 ˚C) (Table 3). 
The Glasgow Coma Scale (GCS) was recorded in 35 (72.9%) of the patients, and of 
these 33 (94.3%) were scored as being 15/15. The two children with GCS less than 15 were 
HIV-positive: a girl of 123 months (10 years) and a boy of 160.6 months (13 years). Both 
presented with headache, meningism and altered mental status. The girl was severely 
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immunocompromised (CD4 count, 7 cells/mm3) and was initiated onto ART during the 
admission. The boy had previously defaulted ART and had been restarted onto therapy, but his 
intercurrent CD4 count was 289 cells/mm3 (severe immunosuppression). The girl had 
cryptococcal fungaemia and meningitis whilst the boy had cryptococcal meningitis. They each 
had more than one lumbar puncture done during their admission, and both had admission 
durations of longer than 21 days.  
Details regarding the presence or absence of photophobia was available in 35 (72.9%) 
of the patient folders, and seven (20%) of these patients presented with photophobia (Table 3).  
Nineteen (52.8%), of the 36 with a note on meningeal irritation in their clinical files, had 
meningism. Papilloedema was observed in one (5%) of 20 children in whose clinical notes this 
clinical finding was reported. Focal signs were present in five (13.5%) of 37 patients (three 
patients had 6th nerve palsy, one had 7th nerve palsy and one had left arm weakness). The 
lumbar puncture opening pressure was recorded in 12 (25%) of the 48 children with laboratory-
confirmed cryptococcosis, and of these 4 (33.3%) had a mean opening pressure of greater than 
25 centimetres of water (Table 3). 
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Medical History 
 
Total 
(n=48) 
HIV 
positive 
(n=38) 
HIV 
negative 
(n=8) 
HIV 
unknown 
(n=2) 
OR (95% CI); P-
value* 
First 
Admission 
 
25 (52.1%) 17 (44.7%) 6 (75.0%) 2 (100.0%) 
3.71 (0.55-40.98); 
0.243^  
Previous 
Hospitalisation 
23 (47.9%) 21 (55.3%) 2 (25.0%) 0 
Presenting Symptoms and Signs 
 Total 
HIV 
positive 
HIV 
negative 
HIV 
unknown 
OR (95% CI); P-
value* 
Fever 
(n=37) 
16 (43.2%) 13 (44.8%)  3 (37.5%)  0 
1.35 (0.21-10.31); 
 0.711  
Headache 
(n=38) 
23 (60.5%) 21 (30.0%)  2 (25.0%) 0 
7.00 (0.95-79.19);  
0.039^ 
Vomiting 
(n=37) 
22 (59.5%) 17 (58.6%)  5 (62.5%) 0 
0.85 (0.11-5.42); 
1.000^ 
Seizures 
(n=37) 
9 (24.3%) 8 (27.6%) 1 (12.5%) 0 
2.66 (0.26-134.97); 
0.649^  
Altered mental status 
(n=37) 
5 (13.5%) 4 (13.8%) 1 (12.5%) 0 
1.12 (0.09-62.93); 
1.000^  
GCS 
(n=35) 
 
GCS<15/15 
 
2 (5.7%) 2 (5.3%) 0 0 
1.000^  
 
GCS 15/15 
 
33 (94.3%) 26 (92.9%) 6 (100.0%) 1 (100.0%) 
Meningism 
(n=36) 
19 (52.8%) 16 (53.3%) 3 (50.0%) 0 
1.14 (0.13-9.94); 
1.000^  
Photophobia 
(n=35) 
7 (20.0%) 6 (21.4%) 1 (14.3%) 0 
1.63 (0.14-87.63); 
1.000^  
Papilloedema 
(n=20) 
1 (5%) 0 1 (25.0%) 0 0.200^  
Focal signs 
(n=37) 
5 (13.5%) 4 (13.8%) 1 (12.5%) 0 
1.12 (0.09-62.93); 
1.000^  
LP 
opening 
pressure 
(cm H2O) 
 
>25 
 
4 (33.3%) 3 (27.3%) 1 (100.0%) 0 
0.333^  
 
≤25 
 
8 (66.7%) 8 (72.7%) 0 0 
Table 3: Clinical presentation of children with laboratory-confirmed cryptococcosis 
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* P-values relate to the comparison of proportions between HIV positive and HIV negative children. 
  ^ Fisher’s exact test. 
 
3.2.3 Disease syndromes in the study population 
 
Twenty-four (50.0%) of the 48 patients had cryptococcal meningitis, 14 (29.2%) had 
cryptococcal meningitis with concomitant cryptococcaemia, and 10 (20.8%) had cryptococcal 
fungaemia without meningitis (Table 4). Apart from meningism, which was significantly more 
frequently observed in children with Cryptococcus cultured on CSF samples compared to those 
who had culture-negative CSF specimens, the clinical presentation of children with laboratory-
confirmed cryptococcal disease was similar regardless of cryptococcal syndrome (Table 4). 
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Presenting Symptoms 
and Signs 
Total 
Cryptococcal 
Fungaemia 
(n=10) 
Dual 
Meningitis 
& 
Fungaemia 
(n=14) 
Cryptococcal 
Meningitis 
(n=24) 
OR (95% CI); P-
value* 
First 
Admission 
25 (52.1%) 8 (80.0%) 8 (57.4%) 9 (37.5%) 
0.20 (0.02-1.24); 
0.075^  Previous 
Hospitalisation 
23 (47.9%) 2 (20.0%) 6 (42.9%) 15 (62.5%) 
Fever 
(n=37) 
16 (43.2%) 5/7 (71.4%) 5/12 (41.7%) 6/18 (33.3%) 
0.23 (0.02-1.78);  
0.202^  
Headache 
(n=38) 
23 (60.5%) 2 (28.6%) 8 (61.5%) 13 (72.2%) 
5.25 (0.68-61.27); 
0.089^  
Vomiting 
(n=37) 
22 (59.5%) 4 (66.7%) 8 (61.5%) 10 (55.6%) 
0.69 (0.06-5.77); 
1.000^  
Seizures 
(n=37) 
9 (24.3%) 1 (16.7%) 3 (23.1%) 5 (27.8%) 
1.74 (0.15-92.38); 
1.000^ 
Altered mental status 
(n=37) 
5 (13.5%) 0 3 (23.1%) 2 (11.1%) 0.567^  
GCS 
(n=35) 
 
GCS<15/15 
 
2 (5.7%) 0 1 (10.0%) 1 (5.6%) 
1.000^  
 
GCS 15/15 
 
33 (94.3%) 7 (100.0%) 9 (90.0%) 17 (94.4%) 
Meningism 
(n=36) 
19 (52.8%) 0 8 (61.5%) 11 (64.7%) 0.006^  
Photophobia 
(n=35) 
7 (20.0%) 0 2 (18.2%) 5 (29.4%) 0.306^  
Papilloedema 
(n=20) 
1 (5.0%) 0 0 1 (8.3%) -^ 
Focal signs 
(n=37) 
5 (13.5%) 0 1 (7.7%) 4 (22.2%) 0.567^  
LP 
opening 
pressure 
(cm H2O) 
>25 4 (33.3%) 0 1 (20.0%) 3 (50.0%) 
1.000^  
≤25 8 (66.7%) 0 4 (80.0%) 3 (50.0%) 
Table 4: Clinical presentation and spectrum of cryptococcal disease in the study population 
* P-values relate to the comparison of proportions between cryptococcal meningitis cases (with or without 
cryptococcaemia) and cases with cryptococcaemia only. 
^ Fisher’s exact test. 
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3.2.4 Concurrent Diagnoses in the study population 
 
Nineteen (39.6%) patients were started on anti-tuberculosis treatment during the course 
of their hospitalisation with laboratory-confirmed cryptococcosis. Three (15.8%) of the children 
initiated on anti-tuberculosis treatment were diagnosed as having tuberculous meningitis, all of 
whom were HIV- positive.  
Thirteen (27.1%) children were treated empirically for concomitant bacterial meningitis. 
Of these 13 patients, ten (77.0%) were HIV-positive and three HIV-negative. 
 Numbers were too small to meaningfully compare CSF pleocytosis and biochemical 
parameters stratified by meningitis type, although there was a trend for children diagnosed with 
TBM to have a higher CSF protein (all three children diagnosed as having TBM had a CSF 
protein greater than 0.50 g/L) compared to those with bacterial meningitis (2/8 (25.0%) had a 
CSF protein greater than 0.50 g/L; P=0.061, exact). 
 
3.3: Cryptococcal Treatment Regimens Used to Treat Children with 
Laboratory-confirmed Cryptococcosis 
 
Treatment regimens used in the management of the children was available upon review 
of 45 (93.8%) of the clinical folders. Thirty-two (71.1%) of these 45 patients received 
amphotericin B for a median of 14 days (IQR, 10.5 to 26 days) at a median dose of 1.0 
mg/kg/day (IQR, 1.0 to 1.1 mg/kg/day), and 13 (28.9%) patients received no amphotericin B. 
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Eighteen (75.0%) of the 24 patients with isolated cryptococcal meningitis and 11 (78.6%) of the 
14 with dual fungaemia and meningitis were treated with amphotericin B, respectively. By 
contrast, three (30.0%) of the 10 children with cryptococcaemia without cryptococcal meningitis 
were treated with amphotericin B. Therefore, children with cryptococcal meningitis were 7.5-fold 
(95% CI, 1.31 to 51.93) more likely to have been treated with amphotericin B compared to those 
who had fungaemia without meningitis, P=0.001 (exact). 
Fluconazole was administered to 28 (62.2%) of the patients with available treatment 
data, for a median 14 days (IQR, 7.5 to 21 days) at a median dose of 10.4 mg/kg/day (IQR, 6.3 
to 16.0 mg/kg/day). Five (41.7%) of the 12 children on fluconazole and concomitant TB 
treatment were on boosted fluconazole dosage regimens (i.e., >10 mg/kg/day). At discharge 28 
(62.2%) patients were on fluconazole prophylaxis. Of the 18 children discharged home without 
fluconazole prophylaxis, 12 (66.7%) were HIV-positive. 
Ten children in the study population (22.2% of those with available treatment data) did 
not receive any anti-fungal therapy during their admission for cryptococcosis. The median age 
of these 10 children was 107 months (8.9 years; IQR, 0.2 to 11.0 years). Five of them were HIV 
positive, 4 were HIV negative and the HIV status of one child was unknown. Six of these 
children died during their admission and the other 4 were discharged home. 
 
 
3.4: Outcomes 
 
The median duration of hospital stay of the study patients was 20 days (IQR, 11 to 34 
days). Thirty-three (68.8%) patients were discharged home and the majority of these (28/33, 
84.8%) were followed up after discharge. The outcome of three patients was unknown: the 
35 
 
parents of two of these (whose ages were 6yrs (HIV-positive, pre-ART) and 12yrs (HIV-
negative) refused further hospital treatment during their admission and left the hospital against 
medical advice, and the records of the other two patients (ages 11 (HIV-unknown) and 12 (HIV-
positive, unknown ART status), did not specify any outcome at all. 
Duration of hospital stay for the two patients whose parents refused further hospital 
treatment were 18 and 21 days, respectively. Three of the four patients with unknown outcome 
had been diagnosed with cryptococcal meningitis and the fourth patient had not had a lumbar 
puncture because of thrombocytopaenia at admission, and was diagnosed with cryptococcal 
fungaemia without meningitis. Amphotericin B and fluconazole therapy were administered to two 
of the four patients during admission; however the treatment details of the other two patients 
were not specified. 
Ten (20.8%) of the 48 patients included in this study population died during the course of 
their hospital admission (Table 5). The majority (9/10) of these patients were 84 months (7 
years) and older and one patient was 30.8 months (2.5 years) old. Half of the children who died 
were being admitted for the second time to hospital and their median duration of hospitalisation 
was two days (IQR, 1 to 5 days). Nine of the children who died were HIV-positive, and only 2/9 
(22.2%) of these were on ART. Amongst HIV-positive children, the odds of dying were 4.7-fold 
(95% CI, 0.68-51.75) higher in those not on ART compare to those who had accessed ART, 
P=0.125 (exact).  
Two of the ten patients that died had cryptococcal meningitis without fungaemia, four 
(40%) had both cryptococcal fungaemia and meningitis and four (40%) had cryptococcal 
fungaemia without meningitis. The odds of dying were 5.5-fold (95% CI, 0.89-57.95) greater in 
children with cryptococcaemia compared to those who had meningitis but who were blood 
culture negative for Cryptococcus, P=0.072. Of the four patients with both cryptococcal 
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fungaemia and meningitis, two received amphotericin B and fluconazole therapy and one 
received amphotericin B only as therapy before he died.  
The majority (7/10) of the children who died during admission with cryptococcal disease 
were also being treated for tuberculosis and one patient had previously completed anti-TB 
treatment. 
Six of the patients who demised did not receive any anti-fungal therapy for cryptococcal 
disease, and they died at a median of 2 days (IQR, 1 to 3 days) into their hospital stay.  
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Table 5: Characteristics of the ten patients that demised in the study population 
ART=antiretroviral therapy  
F=female  
M=male  
 
Neg=negative  
Pos=positive  
N/A=not applicable  
Y=yes; N=no; U=unknown  
B=blood  
C=cerebrospinal fluid  
B/C= blood and cerebrospinal fluid 
Age 
(months) 
Gender 
Admission 
number 
Duration of 
Hospital stay 
(days) 
HIV 
Status 
CD4 Count 
(cells/mm3) 
On ART 
Type of 
Cryptococcal 
Disease 
 
 
Treatment Given 
Amphotericin 
B 
Fluconazole TB Rx 
30.8 M 2 5 Pos Unknown N C N N N 
84 M 2 66 Pos Unknown Y B/C Y Y Y 
89 M 2 2 Pos Unknown N B/C Y N Y 
105 F 1 2 Pos 1 Y B N N Y 
108 F 1 2 Pos Unknown N B N N Y 
131 M 2 1 Pos Unknown N C N N Y 
144 M 1 11 Pos 2 N B/C Y Y Y 
165 F 2 1 Pos 4 N B N N Y 
84 M 1 1 Neg N/A N/A B U U N 
124 M 1 3 Neg N/A N/A B/C N N Y 
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4.0: Discussion 
 
4.1 Summary of Study Findings 
This study describes the spectrum of culture-confirmed cryptococcal disease in children 
managed at three teaching hospitals in Johannesburg over a ten-year period. Fifty-eight 
children, the majority of whom were HIV-positive with severe immunosuppression, were 
identified through a well-established laboratory surveillance network; however, 48 were included 
in the analysis. The median age of the 48 children was 9.6 years and they were generally 
malnourished. 
           Thirty-eight of the children had cryptococcal meningitis with or without concomitant 
cryptococcaemia, and 10 had cryptococcal sepsis without meningitis. The children with 
cryptococcal meningitis were more likely to have been treated with amphotericin B compared to 
those who had fungaemia without meningitis. Almost 40% of the children in the study were 
started on anti-tuberculosis treatment during the course of their hospitalisation with culture-
confirmed cryptococcosis. The median hospital stay of the study patients was 20 days, the 
majority of them were discharged home and 20% died. 
 The majority (38/48) of the children were HIV positive, 22 of which had severe 
immunosuppression. Although HIV infection was the most prevalent underlying predisposing 
factor for cryptococcal disease in this study population, risk factors for cryptococcal disease in 
the HIV-negative children included infancy (n=3) and leukaemia (n=1). The underlying 
predisposing conditions for five patients could not be determined by review of the clinical 
folders.  Most of the HIV-negative children (n=8) had cryptococcal meningitis and one had 
cryptococcal sepsis without meningitis. Half of these patients were treated for cryptococcus and 
one out of the eight died.  
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4.2 Comparison of Study Findings to the Published Literature 
 
                A study done from 42 United States children’s hospitals between 2003 and 2008 
identified 63 children admitted for the treatment of cryptococcal infection with the majority of 
paediatric cryptococcosis occurring in HIV negative patients. However, most patients had other 
immunocompromising medical conditions [21]. 
             Closer to home in Harare, Zimbabwe the records of 13 HIV positive children (≤16 years) 
diagnosed with cryptococcal meningitis between 1995 and 2000 were reviewed in a study 
designed to elucidate features unique to paediatric disease [ref]. The children were compared 
with adult patients with HIV-associated cryptococcal meningitis. Cryptococcal meningitis in 
these African children presented acutely or subacutely and with a fulminant picture consistent 
with progressive meningoencephalitis in the background of severe immune compromise [18]. 
           A comparison of 16, 192 incident cases of cryptococcosis detected through population-
based surveillance was performed from 2005–2007 in South Africa, with 361 (2%) episodes 
occurring among children. This series of 361 cases of paediatric cryptococcosis is one of the 
largest described to date and most children (64%) and adults (63%) were severely 
immunocompromised at the time of diagnosis [17]. 
          From the literature and this study, it is evident that paediatric cryptococcosis is a rare 
condition but that it should be considered in children who are severely immunocompromised 
(and in Southern Africa) especially in the HIV positive paediatric population. 
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4.3 Areas Identified in which Clinical Management deviated from Published 
Guidelines 
 
This study highlighted certain areas in which local practice deviates markedly from 
published guidelines. These centred mostly on the pharmacokinetics of fluconazole and drug-
drug interactions between this agent and rifampicin.  
Rifampicin activates hepatic clearance of fluconazole, so children on fluconazole and 
anti-TB treatment together end up with suboptimal fluconazole drug levels if the fluconazole 
dose is not boosted [11, 20]. In this study five (41.7%) of the 12 children on fluconazole and 
concomitant TB treatment were on boosted fluconazole dosage regimens (i.e., >10 mg/kg/day), 
although published guidelines recommend that patients on dual fluconazole and rifampicin 
therapy ought to be treated with an optimised (15 mg/kg/day) dose of fluconazole [ref HIV 
Clinicians Society Guidelines]. At discharge, 28 (62.2%) patients were on fluconazole 
prophylaxis. Of the 18 children discharged home without fluconazole prophylaxis, 12 (66.7%) 
were HIV-positive. These patients with cryptococcosis received suboptimal care as a result of 
the fluconazole therapy that was deviant from published guidelines. 
Ten (20.8%) of the 48 patients in the study population died during the course of their 
hospital admission. Six of these patients (60%) did not receive any anti-fungal therapy for 
cryptococcal infection, and they died at a median of 2 days (IQR, 1 to 3 days) into their hospital 
stay. Five of these six patients that were not on anti-fungal therapy were HIV-positive and only 
one of them was on ART. This may highlight the fact that cryptococcal disease is not often 
considered in part of the differential diagnosis at admission in ill children presenting at our public 
sector health facilities.  
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There needs to be a high index of suspicion for cryptococcosis in HIV-positive children 
with severe immune-compromise and anti-fungal therapy and ART should be instituted 
timeously as per guidelines. 
 
4.4 Study Limitations 
 
The retrospective nature of this study was a limitation as there were some incomplete 
data from patients’ notes as recorded by the treating clinicians. The clinical parameters looked 
at in the study population’s clinical files were incompletely recorded. Forty-six (95.8%) patients 
had a documented HIV test and two had undefined HIV-infection status. The underlying 
predisposing conditions for five of the eight HIV-negative cryptococcal patients could not be 
determined by review of the clinical records. 
The study was performed in three hospitals in Johannesburg and the sample size (n=48) 
was small which would have impacted on our ability to draw statistically relevant inferences from 
the data.  
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5.0: Conclusion and Recommendation 
   
Paediatric cryptococcosis is a rare condition. In South Africa, HIV infection is an 
important predisposing condition to cryptococcal infection. There appeared to be widespread 
deviation from published guidelines in terms of treating patients with fluconazole at public health 
facilities in Gauteng Province. Clinicians caring for children with cryptococcal disease should 
seek advice from infectious disease clinicians in order to optimise patient care. 
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Appendices 
Appendix 1: Data Collection Tool 
CFR start date: CFR finalised date: 
Sources of data: 
GERMS database/Medical records 
Research case number: 
Hospital: 
CHBAH 
CMJAH 
RMMCH 
Ward: 
Date of Birth: 
Age: 
Months 
Years 
Gender: 
Male 
Female 
Unknown 
Date of admission: Number of previous hospital admissions: 
Is patient referred from another hospital? 
Yes/ No/ Unk  If Yes specify: 
Was patient transferred to another hospital? 
Yes/ No/ Unk     If yes specify: 
 
 
 
44 
 
 
 
Presenting history: 
Main complaint:  
Fever: Yes/No/Unk 
Headache: Yes/No/Unk 
Altered mental state: Yes/No/Unk 
Vomiting: Yes/No/Unk 
Seizures: Yes/No/Unk 
Photophobia: Yes/No/Unk 
Other: Yes/No/Unk  If Yes specify: 
Clinical examination: 
Fever: Yes/No/Unk 
Temp: 
Papilloedema: Yes/No/Unk 
Meningism: Yes/No/Unk 
GSC: 
Altered mental status: Yes/ No/Unk 
Focal signs: Yes/No/Unk  If Yes specify 
LP opening pressure done: Yes/No/Unk 
If Yes specify OP (in cm H2O) 
Other CNS signs: Yes/No/Unk 
If Yes expand: 
Other systems normal: Yes/No/Unk 
If No expand: 
Differential diagnosis: 
Bacterial meningitis: Yes/No/Unk 
TB meningitis: Yes/No/Unk 
Other: 
Site of specimen collection: 
CSF    Blood     Other: 
Date of specimen collection: 
Lab specimen number: 
  
 
45 
 
Was this the first episode of cryptococcosis? 
Yes/No/Unk If Yes When? 
If No, what was the treatment used during 
Previous admission? 
Ampho B       Fluconazole     Other: 
Treatment used in current admission: 
Amphotericin B: Yes/No/Unk 
Dose: 
Duration: 
Fluconazole: Yes/No/Unk 
Dose: 
Duration: 
Other: 
Weight @ diagnosis: 
Duration of stay in hospital: 
Admission date: 
Discharge date: 
 
On discharge did patient receive 
fluconazole: Yes/No/Unk 
Weight:           Dose: 
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CSF results (related to diagnosis): 
Cell count: 
Chemistry: 
Microscopy: gram and India ink: 
Cryptococcal antigen test: 
Bacterial culture: 
Fungal culture: 
TB culture: 
Other: 
Number of LP’s done: 
Last CSF results: 
Cell count: 
Chemistry: 
Microscopy: 
Cryptococcal antigen: 
Bacterial culture: 
Fungal culture: 
TB culture: 
Other: 
 
Patients on Ampho B: 
U+E results on admission: 
U+E results @ discharge: 
Patients on Ampho B: 
U+E/Hb/Mg monitored 2x or more during 
admission: Yes/No/Unk   If Yes specify 
Was patient tested for HIV? Yes/No/Unk 
If Yes, HIV status:  
Positive/Negative/Unknown 
 
For HIV-infected patients: ART use: 
Perinatal: Yes/No/Unk 
ART: Yes/No/Unk 
CD4 count at admission: Last CD4 count: 
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Viral load at admission: Last Viral load: 
Other conditions predisposing patient to 
infection (apart from HIV): 
Malignancy: 
Organ transplant: 
Steroid use: 
Unknown: 
Other(specify): 
Confirmed TB: Yes/No/Unk 
Current TB treatment: 
 
Previous TB treatment: 
Radiological studies: 
CXR/CT Brain/Other 
Radiological findings: 
For patients who were discharged: 
Neurological status @ discharge: 
Intact/ Unknown/Not Intact   Specify: 
Data collector: Patient outcome: 
Discharged: Home/Follow Up/Unknown 
Died: 
Absconded/RHT: 
Unknown: 
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Appendix 2: Ethics Clearance Certificate 
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Appendix 3: Hospital Permission Letters 
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Appendix 4: CDC HIV Immunologic Classification Table 
 
Immunologic categories based on age-specific CD4+ T-lymphocyte counts 
and percent of total lymphocytes 
 
Immunologic category                                         Age of child 
 
<12 mnths 1–5 yrs 6–12 yrs 
 
L                 (%) L                   (%) L                 (%) 
1: No evidence of suppression 1,500        (25) 1,000         (25) 500           (25) 
 
2: Evidence of moderate suppression 750– 
       1,499 (15–24) 
 
500– 
          999 (15–24) 
 
200– 
         499 (15–24) 
 
3: Severe suppression <750           (<15) <500             (<15) <200            (<15) 
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